Table 6.
Clinical outcomes of patients with detectable human anti-chimeric antibodies or subtherapeutic infliximab concentrations
| Response to test | Complete/partial response (%) | P value | |
|---|---|---|---|
| Detectable HACA | Increase infliximab | 1/6 (17) | P < 0.004 |
| Change anti-TNF | 11/12 (92) | ||
| Subtherapeutic concentration | Increase infliximab | 25/29 (86) | P < 0.016 |
| Change anti-TNF | 2/6 (33) |
HACA, human anti-chimeric antibody; TNF, tumor necrosis factor.